RWM
LGND icon

Rialto Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Rialto Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949 Buy
3
+2
+200% +$471 ﹤0.01% 1401
2026
Q1 		$200 Hold
1
– – ﹤0.01% 1600
2025
Q4 		$190 Buy
+1
New +$192 ﹤0.01% 1534

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rialto Wealth Management's LGND Position: Q2 2026 in Review

Rialto Wealth Management increased its Ligand Pharmaceuticals (LGND) stake by 200% in Q2 2026, buying an estimated $471 and bringing the position to 3 shares worth $949. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

Rialto Wealth Management first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Rialto Wealth Management held 3 shares of Ligand Pharmaceuticals worth $949 as of Q2 2026.
  • Rialto Wealth Management bought 2 Ligand Pharmaceuticals shares in Q2 2026, an estimated $471.
  • Ligand Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1401 holding.
  • Rialto Wealth Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.